This study examined whether administering neoadjuvant therapy (nat) followed by surgical resection is safe and effective in pancreatic ductal adenocarcinoma (PDAC) patients aged 75 and older. In a comprehensive three-part analysis, the research found that this aggressive treatment approach appears to be both safe and effective for older patients. Notably, it led to improved outcomes […]

Researchers have successfully validated the accuracy of two fistula risk scores, “distal fistula risk scores” and “dispair,” in predicting postoperative pancreatic fistula (POPF) after distal pancreatectomy. These scores are based on various patient factors like body mass index, diabetes, and pancreatic characteristics. With a 19.3% incidence of clinically relevant POPF in their cohort, the study […]

Researchers compared treatments for common bile duct (CBD) stones, and ultrasound-guided percutaneous transhepatic cholangioscopic lithotripsy (PTCSL) stood out. PTCSL outperformed laparoscopic exploration, with better perioperative outcomes and fewer complications. It also beat endoscopic treatment with fewer instances of pancreatitis, reflux esophagitis, and papillary stenosis. Additionally, the study identified gallstones and family history as independent risk […]

A systematic review and meta-analysis explored whether the presence of an aberrant right hepatic artery (A-RHA) influences outcomes after pancreaticoduodenectomy (PD). Results indicate that A-RHA doesn’t significantly affect critical endpoints, such as tumor margin (R1) rate, overall survival, morbidity, mortality, and biliary fistula rate. Additionally, non-critical outcomes like postoperative pancreatic fistula, delayed gastric emptying, post-pancreatectomy […]

Researchers compared the outcomes of liver-confined unresectable intrahepatic cholangiocarcinoma (ICCA) patients receiving systemic chemotherapy (gemcitabine and cisplatin) with those given hepatic arterial infusion pump (HAIP) chemotherapy. The study, involving 268 patients, revealed that HAIP chemotherapy significantly outperformed systemic treatment. Median survival for HAIP was 27.7 months compared to 11.8 months with gem-cis. Notably, HAIP resulted […]